---ENDOCANS---
Endocan Research Products
Product Line Summary
Endocan Proteins - recombinant expressed and purified proteins
Endocan ELISA Development Kits - Reagents to produce ELISA tests in your lab; or purchase a complete kit.
Ancillary Products for Endocan ELISA Kits - standards and buffers for ELISA development
Endocan, also known as endothelial cell-specific molecule (ESM-1), is encoded by a single non-polymorphic gene (esm1) and was originally discovered by Lassalle and collaborators in endothelial cells. Structurally, endocan is a dermatan sulfate proteoglycan of 50 kDa (165aa) that is freely circulating in blood. Endocan binds CD11a/CD18 integrin (also called LFA-1 for Leukocyte Function-associated Antigen1) on human leukocytes inhibiting consequently its binding to ICAM-1 and transendothelial migration. Moreover, endocan has been recently described as a biomarker of tip cells and neoangiogenesis. Endocan expression is upregulated by pro-inflammatory molecules such as tumor necrosis factor alpha, and pro-angiogenic molecules including TNF , IL-1, VEGF or FGF-2. Its synthesis and secretion decrease by activation of the endothelial PI3K pathway induced by a variety of mediators such as gamma interferon or insulin. Circulating endocan declines through an activated neutrophil-induced proteolytic process, generating a circulating cleaved form of 14 kDa. Endocan binds via its dermatan sulfate chain to hepatocyte growth factor/ scatter factor.
Endocan appears as a pertinent biomarker of endothelial dysfunction. Biothelis offers numerous Research Use Only products for laboratories studying the Endocan molecule. Endocan has been described as a biomarker of pulmonary endothelial dysfunction. Early variations of blood levels of Endocan have been shown to predict nosocomial pneumonia or acute respiratory failure depending on the clinical context: septic shock, polytrauma, thoracic surgery, mechanical ventilation, and COVID19 (De Freitas Caires N et al,, Crit Care, 2018, review).
Indeed, BIOTHELIS is now introducing the measurement of blood endocan as an in vitro diagnostic medical device in French university Hospitals like Lille and Paris. Additionally, Endocan has also been shown to be strongly associated with angiogenesis, particularly involved in tumor growth. Nevertheless, much remains to be done to fully understand the real functions of endocan, BIOTHELIS offers the best tools for exploring the functions of human and animal endocan in experimental designs. Biothelis antibodies are all purified by affinity chromatography in native conditions, tested for their activities, and stored without preservatives.
A new clinical Concept
Endocan exhibits anti-inflammatory activity, acting as an inhibitor of the leukocyte integrin-dependent activation cascade LFA-1. By preventing the entry of leukocytes into the interstitial tissues, endocan reduces inflammation. Thus, a high level of endocan in acute or chronic inflammatory syndromes would protect against inflammation, and would have a good prognosis. Conversely, a low level of endocan in these syndromes would be a poor prognosis or predictor of a pathological event.
New clinical applications
Clinical research has established endocan as a diagnostic biomarker for the endothelial response that occurs in many diseases. IV administration of LPS in humans induces an increase in human plasma endocan which correlates with a defective vasodilator response to acetylcholine. An increase or decrease in endocan identifies patients at risk for pulmonary infection / aggression or tumor aggression.
The dosage of circulating endocan can be useful to the patient in different ways:
- Early diagnosis to allow earlier start of treatment (ARDS, hepatocarcinoma),
- Risk stratification (pneumonia),
- The prognosis (cirrhosis, oncology),
- The response to treatment (oncology),
- Reducing hospital costs.
All products on this page are for research use only and not for dianostic or therapeutic use.
ANTIBODIES
| Name | Clone | Specificity | Reactivity | Application | Size | Cat. No. |
| Anti-Endocan mAb(Clone MEP08) | MEP08 |
N-termnal |
Chicken, Monkey, Human | IHC | 100 µg | BTL-LIA-0901 |
| Anti-Endocan mAb (Clone MEP21) | MEP21 | N-termnal | Human | WB | 100 µg | BTL-LIA-0902 |
| Anti-Endocan mAb (Clone GGR222) | GGR222 | N-terminal | Mouse, Rat | WB | 100 µg | BTL-LIA-0905 |
| Anti-Endocan mAb (Clone MEP14) | MEP14 | C-terminal | Human, Chicken, Rat, Porcine, Mouse, Monkey | IHC, ELISA, WB | 100 µg | BTL-LIA-1001 |
| Anti-Endocan mAb (Clone MEC15) | MEC15 | N-termnal | Human, Monkey | ELISA, FC, WB | 100 µg | BTL-LIA-1002 |
| Anti-Endocan mAb (Clone MEP19) | MEP19 | C-termnal | Human | IP | 100 µg | BTL-LIA-1003 |
| Anti-Endocan mAb (Clone GGR237) | GGR237 | internal | Mouse, Rat | IP | 100 µg | BTL-LIA-1101 |
PROTEINS
| Name | Clone | Reactivity | Application | Size | Cat. No. |
| bioassay, western blot | 10 µg |
BTL-LIP-1001-10U
|
|||
| bioassay, western blot | 50 µg |
BTL-LIP-1001-50U
|
|||
| bioassay, western blot | 10 µg |
BTL-LIP-1002-10U
|
|||
| bioassay, western blot | 50 µg |
BTL-LIP-1002-50U
|
ELISA Development KITS
| Name | Designation | Specificity | Description | Reactivity | Application | Size | Cat. No. |
| DIYEK H1 |
Human Endocan/ESM-1 Monkey Endocan/ESM-1 |
To realize two 96 well plates | Human, Monkey | ELISA Development | 2 x 96 rxns | BTL-LIK-1101 | |
| DIYEK H1 |
Human Endocan/ESM-1 |
To realize five 96 well plates | Human, Monkey | ELISA Development | 5 x 96 rxns | BTL-LIK-1101B5 | |
| DIYEK H1 |
Human Endocan/ESM-1 |
To realize ten 96 well plates | Human, Monkey | ELISA Development | 10 x 96 rxns |
BTL-LIK-1101B10
|
|
| DIYEK H1 |
Human Endocan/ESM-1 |
To realize twenty-five 96 well plates | Human, Monkey | ELISA Development | 25 x 96 rxns |
BTL-LIK-1101B25
|
|
| DIYEK H1 |
Mouse Endocan/ESM-1 |
To realize two 96 well plates | Mouse | ELISA Development | 2 x 96 rxns | BTL-LIK-1102 | |
| DIYEK H1 |
Rat Endocan/ESM-1 |
To realize two 96 well plates | Rat | ELISA Development | 2 x 96 rxns | BTL-LIK-1103 | |
| DIYEK H1 |
Human Endocan/ESM-1 Complete ELISA KIT |
Ready to use ELISA Kit with all buffers and reagents | Human | ELISA | 1 x 96 rxns | BTL-LIK-1205 | |
| DIYEK H1 |
Human Endocan and CG-cleaved Endocan |
To realize one 96 well plate for each biomarker | Human | ELISA Development | 1 x 96 rxns (analyze 160 samples) |
BTL-LIK-1501 | |
| DIYEK H1 |
Human Endocan and CG-cleaved Endocan |
To realize five 96 well plate for each biomarker / | Human | ELISA Development | 5 x 96 rxns (analyze 400 samples) |
BTL-LIK-1501B5
|
|
| DIYEK H1 |
Human Endocan and CG-cleaved Endocan |
To realize ten 96 well plate for each biomarker | Human | ELISA Development | 10 x 96 rxns (analyze 800 samples) |
BTL-LIK-1501B10
|
|
| DIYEK H1 |
Human Endocan and CG-cleaved Endocan |
To realize twenty-five 96 well plate for each biomarker | Human | ELISA Development | 25 x 96 rxns (analyze 2200 samples) |
BTL-LIK-1501B25
|
|
Ancillary Products for ELISA Development |
|||||||
| Standard Human Endocan/ESM-1 | ELISA Development | 100 ng | BTL-LIP-1101 | ||||
| Standard Murine Endocan/ESM-1 | ELISA Development | 100 ng | BTL-LIP-1104 | ||||
| Buffer B (10X) | ELISA Development | 100 ml | BTL-LIP-1201 | ||||
| Buffer C (10X) | ELISA Development | 10 ml | BTL-LIP-1202 | ||||
| ELISA Buffer (20X) | ELISA Development | 75 ml | BTL-LIP-1206 | ||||